Equity Overview
Price & Market Data
Price: $1.96
Daily Change: +$0.13 / 6.63%
Daily Range: $1.90 - $1.98
Market Cap: $551,254,272
Daily Volume: 7,245
Performance Metrics
1 Week: 12.96%
1 Month: -20.43%
3 Months: -14.49%
6 Months: -33.21%
1 Year: 209.1%
YTD: -18.30%
Company Details
Employees: 231
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.